Alternatives to Intellia Therapeutics

A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.

Develops advanced gene editing and cell therapy solutions for rare genetic diseases.

Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology.

Developing gene editing therapies to lower cholesterol.

Scalable, one-time curative in-vivo gene editing therapies.

Developing gene editing therapies for rare genetic diseases.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

VI Therapeutics is developing novel therapies for rare genetic diseases.

Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.

Leveraging the adaptive immune system to diagnose and treat disease.

A global oncology company developing and commercializing innovative cancer treatments.

Developing engineered biologics to harness the immune system for disease treatment.

Clinical-stage genetic medicine company developing AAV-mediated treatments for cardiovascular and Alzheimer's diseases.

Caris Life Sciences is a leading innovator in molecular science, offering precision medicine solutions for cancer patients through advanced molecular profiling.

Developing novel therapeutics targeting dysfunctional DNA packaging for diseases like cancer.

Biotechnology company focused on developing treatments for rare metabolic diseases.

Guardant Health is a precision oncology company that develops and commercializes liquid biopsy tests for cancer detection, recurrence monitoring, and treatment selection.

Biopharmaceutical company focused on developing and commercializing innovative treatments for rare neurological disorders.

Clinical-stage biotech company developing AAV gene therapies for rare and retinal diseases.

AI-powered platform for personalized cell therapy development and manufacturing.